FIRAPY Supports Clinical Research Advancing Non-Invasive Therapies for Peritoneal Dialysis

July 2, 2025

We are pleased to share that a new peer-reviewed clinical study, conducted in collaboration with Taipei Veterans General Hospital, has been published in the Journal of the Formosan Medical Association (JFMA, 2025).
The study, titled
“Far-infrared therapy improves cardiovascular and infectious outcomes in peritoneal dialysis patients: A propensity-score matched cohort study,”
represents a significant milestone in FIRAPY’s ongoing academic engagement in dialysis-related research.

Long-Term Collaboration to Explore Non-Invasive Therapeutic Strategies

Over the past several years, the FIRAPY team has actively collaborated with hospital-based research groups and nephrology departments to support the development of non-invasive therapeutic approaches for dialysis patients. These joint research efforts have focused on key challenges in peritoneal dialysis, including:

  • Inflammatory burden
  • Cardiovascular complications
  • Peritoneal membrane function
  • Infection-related outcomes

This newly published study marks the sixth peer-reviewed paper supported by FIRAPY in this field and underscores our ongoing commitment to advancing scientific research that aims to improve patient outcomes through non-invasive care modalities.

About the Latest Publication

Led by the nephrology team at Taipei Veterans General Hospital, the study employed a propensity score-matched cohort design to evaluate long-term outcomes in peritoneal dialysis patients. The results suggest that the use of far-infrared therapy may be associated with reduced cardiovascular and infectious complications, offering promising insights for future clinical exploration.

We extend our sincere thanks to the research team at TVGH for their dedication and leadership, and we look forward to continuing our support for high-quality, collaborative research in kidney care.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
FIR improves cardiovascular and infectious outcomes inPD patients

Far-infrared therapy improves cardiovascular and infectious outcomes in peritoneal dialysis patients

July 2, 2025
Abstract

FIRAPY to Exhibit at 70th JSDT Annual Meeting in Yokohama

June 17, 2025
We are pleased to announce that FIRAPY will be exhibiting at the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , to be held in OSAKA , Japan , from June 27-29, 2025 . 📍 Booth No.: ⑩-96 📅 June 27–29, 2025 📌 Osaka International Convention Center 🔗 Event Website (Japanese) FIRAPY is now adopted by over 200 dialysis facilities across Japan , where it has been used in daily clinical practice to support fistula function maintenance and foot care . With this extensive local experience, FIRAPY has become an important part of non-invasive treatment for Japanese HD patients. We look forward to sharing our latest clinical insights and field experiences at JSDT 2025. If you are attending, we warmly welcome you to stop by Booth ⑩-96 and learn more about how FIRAPY is making a difference in dialysis care. See you in Osaka!
FIRAPY was showcased at ERA 2025 in Vienna, where we reconnected with partners and met new potential

FIRAPY Showcased at ERA 2025 in Vienna

June 8, 2025
FIRAPY Medical was honored to exhibit at ERA 2025 , held at Austria Center Vienna from June 4–7, 2025 . This event marked FIRAPY’s first return to the ERA Congress since the global COVID-19 pandemic , and an important milestone in reconnecting with the European nephrology community. During the congress, our booth (X1.200) attracted considerable attention from both existing partners and new contacts. We were very encouraged by the many productive conversations and the strong interest shown by nephrology professionals across different regions. It was a great pleasure to meet some of our long-standing friends at the event, including: Stanningley Pharma (UK) — our valued distribution partner in the UK for more than 15 years Dr. Dan Heristea (France) — a nephrology expert and friend of FIRAPY Nordic MedCom (Nordic) — a familiar face from past interactions in the industry We were equally pleased to engage with potential new partners from Canada, Morocco, Panama, and the UAE . We look forward to the possibility of building new collaborations to further extend the clinical benefits of FIRAPY to more patients worldwide.  We sincerely thank everyone who visited our booth and supported us throughout the congress. We look forward to continuing these conversations and working together to advance vascular access care and patient outcomes through FIRAPY.
More Posts